Is CelLBxHealth plc (ANPCY) a Buy, Sell, or Hold?
CelLBxHealth plc
OTC:ANPCY
$0.067 USD
$0 (0.0%)
- Volume
- 20.02K
- Average Volume
- 19.15K
- Market Capitalization
- $21.98M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $
- Year High
- $2.39
- Year Low
- $0.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $
- Current Ratio
- $
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Peter Collins |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | ANPCY |
| CUSIP | 03476V100 |
| CIK | None |
| Web | https://cellbxhealth.com |
| Phone | 44 14 8334 3434 |
| Currency | USD |
| Employees | 119 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | |
| Payout Ratio | |
| Current Ratio | |
| Quick Ratio | |
| Cash Ratio |
Sales & Book Value
| Annual Sales | $2.86M |
| Price / Sales | |
| Cash Flow | |
| Price / Cash Flow | |
| Price / Book |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.48 |
| Trailing P/E Ratio | |
| PEG Ratio | |
| P/E Growth | |
| Net Income | $-14.22M |
| Net Margin | % |
| Pretax Margin | % |
| Return on Equity | % |
| Return on Assets | % |
Financials Score
| AltmanZ Score | -11.88 |
| Piotroski Score | 2.00 |
| Working Capital | 6.72M |
| Total Assets | 18.08M |
| Ebit | -16.47M |
| Market Cap | 16.4M |
| Total Liabilities | 6.39M |
Poll Results
About CelLBxHealth plc (OTC:ANPCY) Stock
Headquartered in Guildford, United Kingdom, and established in 1994, CelLBxHealth plc (formerly known as ANGLE plc until October 2025) is a medical diagnostics company dedicated to advancing cancer detection. The firm's reach extends globally, with operations in the UK, Europe, and North America. CelLBxHealth's product portfolio features innovative medical devices such as the Parsortix PC1 system, specifically engineered to isolate and collect intact circulating tumor cells (CTCs) from the blood of metastatic breast cancer patients for subsequent user-validated analysis. They also offer the Parsortix PR1 system for general CTC capture. Further enhancing their diagnostic capabilities are the Portrait+ CTC Staining kit, a ready-to-use laboratory tool providing high analytical sensitivity and ... specificity for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs, alongside the CellKeep Slide for efficient CTC harvesting. In addition to its product line, the company provides comprehensive laboratory services, including CTC enrichment and liquid biopsy analysis. Their specialized assays encompass Portrait Flex, an immunofluorescence test for identifying epithelial, mesenchymal, and epithelial-to-mesenchymal transition (EMT) cells, as well as assessing DNA damage response. They also offer Portrait PD-L1 for evaluating CTCs and develop bespoke CTC assays. Strategic alliances are a key component of their development strategy, including a partnership with BioView Ltd to create a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. to leverage a pan-cancer next-generation sequencing (NGS) panel.
2026-07-01 09:30:00
New season, "AI at Work: From Promise to Impact," examines where artificial intelligence may create lasting value, where expectations may be too high, and what investors should watch as adoption moves into the real economy BALTIMORE, July 1, 2026 /PRNewswire/ -- The newest season of "The Angle from T. Rowe Price" podcast debuts today, where the global investment management firm and a leader in retirement convenes some of its leading investment professionals to help listeners separate myth from reality about the burgeoning artificial intelligence sector.
CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration
2026-04-20 06:01:43
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) shares rose 8% to 0.99p after the AIM-listed circulating tumour cell specialist announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease.
CelLBxHealth joins forces with The Royal Marsden on lung cancer liquid biopsy study
2026-04-20 02:30:01
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), a specialist in circulating tumour cell (CTC) analysis, has announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease.
Frequently Asked Questions
-
What is the current CelLBxHealth plc (ANPCY) stock price?
-
CelLBxHealth plc(OTC:ANPCY) stock price is $0.067 in the last trading session. During the trading session, ANPCY stock reached the peak price of $2.39 while $0.0666 was the lowest point it dropped to. The percentage change in ANPCY stock occurred in the recent session was 0.0% while the dollar amount for the price change in ANPCY stock was $0.
-
ANPCY's industry and sector of operation?
-
The OTC listed ANPCY is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of ANPCY?
-
Lauren Arthy-Miles | ESG Lead
Peter Collins | Chief Executive Officer
Anne-Sophie Pailhes-Jimenez | Head of R&D and Senior Director
Michelle Munson | Human Resources Director
Sinéad Armstrong | Finance Director -
How many employees does ANPCY have?
-
Number of ANPCY employees currently stands at 119. ANPCY operates from Surrey Research Park, Guildford, None GU2 7AF, GB.
-
Link for ANPCY official website?
-
Official Website of ANPCY is: https://cellbxhealth.com
-
How do I contact ANPCY?
-
ANPCY could be contacted at phone #44 14 8334 3434 and can also be accessed through its website. ANPCY operates from Surrey Research Park, Guildford, None GU2 7AF, GB.
-
How many shares of ANPCY are traded daily?
-
The average number of ANPCY shares traded daily for last 3 months was 19.15K.
-
What is the market cap of ANPCY currently?
-
The market value of ANPCY currently stands at $21.98M with its latest stock price at $0.067